AROAF
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more
AROAF (AROAF) - Net Assets
Latest net assets as of March 2025: $84.59 Million USD
Based on the latest financial reports, AROAF (AROAF) has net assets worth $84.59 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($98.94 Million) and total liabilities ($14.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $84.59 Million |
| % of Total Assets | 85.5% |
| Annual Growth Rate | 12.04% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 33.61 |
AROAF - Net Assets Trend (2021–2025)
This chart illustrates how AROAF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AROAF (2021–2025)
The table below shows the annual net assets of AROAF from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $84.59 Million | -2.87% |
| 2024-03-31 | $87.09 Million | -8.69% |
| 2023-03-31 | $95.38 Million | +2.11% |
| 2022-03-31 | $93.40 Million | +73.96% |
| 2021-03-31 | $53.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AROAF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1897533417.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $142.81 Million | 168.82% |
| Total Equity | $84.59 Million | 100.00% |
AROAF Competitors by Market Cap
The table below lists competitors of AROAF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP
|
$103.31 Million |
|
Taiyen Biotech Co Ltd
TW:1737
|
$103.31 Million |
|
DIAMOND BIOFUND INC
TW:6901
|
$103.34 Million |
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
$103.35 Million |
|
Namsun Alumini
KO:008350
|
$103.30 Million |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
$103.29 Million |
|
Talga Group Ltd
PINK:TLGRF
|
$103.27 Million |
|
Vaxcell-Bio Therapeutics Co. Ltd
KQ:323990
|
$103.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AROAF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,091,093 to 84,591,967, a change of -2,499,126 (-2.9%).
- Net loss of 3,465,104 reduced equity.
- Share repurchases of 1,347,692 reduced equity.
- New share issuances of 9,088 increased equity.
- Other factors increased equity by 2,304,582.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.47 Million | -4.1% |
| Share Repurchases | $1.35 Million | -1.59% |
| Share Issuances | $9.09K | +0.01% |
| Other Changes | $2.30 Million | +2.72% |
| Total Change | $- | -2.87% |
Book Value vs Market Value Analysis
This analysis compares AROAF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.24x to 1.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | $0.18 | $0.40 | x |
| 2022-03-31 | $0.27 | $0.40 | x |
| 2023-03-31 | $0.28 | $0.40 | x |
| 2024-03-31 | $0.25 | $0.40 | x |
| 2025-03-31 | $0.25 | $0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AROAF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.50%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.17x
- Recent ROE (-4.10%) is above the historical average (-11.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -32.84% | -85.98% | 0.28x | 1.36x | $-23.00 Million |
| 2022 | -8.35% | -21.13% | 0.35x | 1.12x | $-17.13 Million |
| 2023 | -0.39% | -0.62% | 0.54x | 1.14x | $-9.91 Million |
| 2024 | -11.19% | -15.39% | 0.62x | 1.17x | $-18.46 Million |
| 2025 | -4.10% | -4.50% | 0.78x | 1.17x | $-11.92 Million |
Industry Comparison
This section compares AROAF's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AROAF (AROAF) | $84.59 Million | -32.84% | 0.17x | $103.30 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |